191 related articles for article (PubMed ID: 35653850)
1. Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience.
Steidl C; Aroldi A; Mologni L; Crespiatico I; Fontana D; Mastini C; Fumagalli M; Perfetti P; Borin L; Valentini C; Piazza R; Gambacorti-Passerini C
Leuk Res; 2022 Jul; 118():106861. PubMed ID: 35653850
[TBL] [Abstract][Full Text] [Related]
2. Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.
Kim JJ; Jang JE; Lee HA; Park MR; Kook HW; Lee ST; Choi JR; Min YH; Shin S; Cheong JW
Ann Lab Med; 2023 Jul; 43(4):328-336. PubMed ID: 36843401
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
4. An NGS based MRD evaluation from acute myeloid leukemia patients.
Chen B; Wang L; Wang Z; Zhang H; Chen L; Zhang L; Li J; Yan X; Zhao M; Lin Y; Ru K
Int J Lab Hematol; 2023 Jun; 45(3):353-359. PubMed ID: 36751002
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
6. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
8. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
Shapiro RM; Kim DDH
Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
Kim HJ; Kim Y; Kang D; Kim HS; Lee JM; Kim M; Cho BS
Blood Cancer J; 2021 Jun; 11(6):109. PubMed ID: 34088902
[TBL] [Abstract][Full Text] [Related]
11. Novel Tools for Diagnosis and Monitoring of AML.
Guijarro F; Garrote M; Villamor N; Colomer D; Esteve J; López-Guerra M
Curr Oncol; 2023 May; 30(6):5201-5213. PubMed ID: 37366878
[TBL] [Abstract][Full Text] [Related]
12. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
Hughes CFM; Gallipoli P; Agarwal R
Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
[TBL] [Abstract][Full Text] [Related]
13. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
[TBL] [Abstract][Full Text] [Related]
14. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
Yu T; Chi J; Wang L
Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
[TBL] [Abstract][Full Text] [Related]
15. The role of next-generation sequencing in acute myeloid leukemia.
Llop M; Sargas C; Barragán E
Curr Opin Oncol; 2022 Nov; 34(6):723-728. PubMed ID: 36102349
[TBL] [Abstract][Full Text] [Related]
16. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.
Tsai CH; Tang JL; Tien FM; Kuo YY; Wu DC; Lin CC; Tseng MH; Peng YL; Hou MF; Chuang YK; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
Blood Adv; 2021 May; 5(10):2456-2466. PubMed ID: 33999144
[TBL] [Abstract][Full Text] [Related]
18. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.
Heuser M; Heida B; Büttner K; Wienecke CP; Teich K; Funke C; Brandes M; Klement P; Liebich A; Wichmann M; Neziri B; Chaturvedi A; Kloos A; Mintzas K; Gaidzik VI; Paschka P; Bullinger L; Fiedler W; Heim A; Puppe W; Krauter J; Döhner K; Döhner H; Ganser A; Stadler M; Hambach L; Gabdoulline R; Thol F
Blood Adv; 2021 May; 5(9):2294-2304. PubMed ID: 33929500
[TBL] [Abstract][Full Text] [Related]
19. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML.
Stasik S; Burkhard-Meier C; Kramer M; Middeke JM; Oelschlaegel U; Sockel K; Ehninger G; Serve H; Müller-Tidow C; Baldus CD; Röllig C; Bornhäuser M; Platzbecker U; Thiede C
Blood Adv; 2022 Jun; 6(11):3294-3303. PubMed ID: 35320339
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
Owattanapanich W; Herzig J; Jahn N; Panina E; Ruchutrakool T; Kungwankiattichai S; Issaragrisil S; Döhner H; Döhner K
Ann Hematol; 2021 Aug; 100(8):1983-1993. PubMed ID: 33839881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
